Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen (Nasdaq: SRZN) will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025. Management will hold a fireside chat at 6:30 AM Pacific Time / 9:30 AM Eastern Time. Interested parties can listen to the audio webcast via the Investors section of Surrozen's website and a replay will be archived at www.surrozen.com. The presentation covers company developments in targeted Wnt pathway therapeutics for severe eye diseases and is intended for investors and healthcare stakeholders.
Surrozen (Nasdaq: SRZN) parteciperà alla Guggenheim 2ª Conferenza annuale sull'Innovazione nel settore sanitario il 12 novembre 2025. Il management terrà una chiacchierata informale alle 6:30 AM Pacific Time / 9:30 AM Eastern Time. Le parti interessate potranno ascoltare la trasmissione audio webcast tramite la sezione Investitori del sito di Surrozen e una replica sarà archiviata su www.surrozen.com. La presentazione riguarda gli sviluppi dell'azienda nel campo dei terapie mirate della via Wnt per malattie oculari gravi ed è destinata a investitori e a stakeholder nel settore sanitario.
Surrozen (Nasdaq: SRZN) participará en la Conferencia anual de innovación en salud de Guggenheim 2ª edición el 12 de noviembre de 2025. La dirección realizará una charla informal a las 6:30 AM hora del Pacífico / 9:30 AM hora del Este. Las partes interesadas pueden escuchar la transmisión de audio en webcast a través de la sección de Inversionistas del sitio web de Surrozen y una repetición quedará archivada en www.surrozen.com. Las parte s interesadas pueden escuchar la transmisión de audio en webcast a través de la sección de Inversionistas del sitio web de Surrozen y una repetición quedará archivada en www.surrozen.com. La presentación aborda los avances de la empresa en terapéuticas dirigidas a la vía Wnt para enfermedades oculares graves y está destinada a inversores y actores del sector de la salud.
Surrozen (Nasdaq: SRZN)은 2025년 11월 12일 개최되는 구겐하임 2회째 연례 헬스케어 혁신 컨퍼런스에서 발표할 예정입니다. 경영진은 태평양 표준시 6:30 / 동부 표준시 9:30에 파이어사이드 채팅을 진행합니다. 관심 있는 분들은 Surrozen 웹사이트의 투자자 섹션을 통해 오디오 웹캐스트를 들을 수 있으며 재방송은 www.surrozen.com에 보관됩니다. 발표는 시력 관련 심각한 질환을 위한 표적 Wnt 경로 치료제 개발 현황을 다루며 투자자와 헬스케어 이해관계자들을 위한 내용입니다.
Surrozen (Nasdaq: SRZN) participera à la Guggenheim 2e Conférence annuelle sur l'innovation en santé le 12 novembre 2025. La direction animera une conversation informelle à 6h30, heure du Pacifique / 9h30, heure de l'Est. Les parties intéressées peuvent écouter la webcast audio via la section Investisseurs du site de Surrozen et une rediffusion sera archivée sur www.surrozen.com. La présentation couvre les évolutions de l'entreprise dans les thérapies ciblées de la voie Wnt pour les maladies oculaires graves et s'adresse aux investisseurs et aux parties prenantes du secteur de la santé.
Surrozen (Nasdaq: SRZN) wird am 11. Dezember 2025 der Guggenheim 2nd Annual Healthcare Innovation Conference präsentieren. Das Management wird eine Kamingespräch um 6:30 Uhr Pacific Time / 9:30 Uhr Eastern Time führen. Interessierte können die Audio-Webcast über den Bereich Investors auf der Surrozen-Website anhören, und eine Wiedergabe wird unter www.surrozen.com archiviert. Die Präsentation behandelt Unternehmensentwicklungen im Bereich gezielter Wnt-Weg-Therapeutika für schwere Augenerkrankungen und richtet sich an Investoren und Gesundheitsakteure.
Surrozen (Nasdaq: SRZN) ستقدم في مؤتمر Guggenheim للابتكار في الرعاية الصحية السنوي الثاني في 12 نوفمبر 2025. ستعقد الإدارة جلسة حوار غير رسمية في الساعـة 6:30 صباحاً بتوقيت المحيط الهادئ / 9:30 صباحاً بتوقيت شرق الولايات المتحدة. يمكن للأطراف المعنية الاستماع إلى البث الصوتي عبر الويب عبر قسم المستثمرين على موقع Surrozen، وسيتم أرشفة إعادة البث على www.surrozen.com. تتناول العرض التطورات في الشركات في علاجات موجهة عبر مسار Wnt لاضطرابات العين الشديدة وهو مخصص للمستثمرين وأصحاب المصلحة في قطاع الرعاية الصحية.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference.
Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025
Surrozen Fireside Chat at 6:30 AM Pacific Time/9:30 AM Eastern Time
Interested parties may access the audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcast will be archived on the website at www.surrozen.com.
About Surrozen
Surrozen is a biotechnology company developing tissue-specific antibodies to selectively modulate the Wnt pathway, with a current focus on ophthalmology. Its proprietary technologies aim to harness the body’s biological repair mechanisms to treat severe diseases. For more information, please visit surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: Investorinfo@surrozen.com
FAQ
When will Surrozen (SRZN) present at the Guggenheim Healthcare Innovation Conference?
What time is the Surrozen (SRZN) fireside chat on November 12, 2025?
How can investors access the Surrozen (SRZN) webcast for the conference?
Will Surrozen (SRZN) provide a replay of the conference presentation?
What topics will Surrozen (SRZN) likely cover in the November 12, 2025 presentation?
